KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EBITDA (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of EBITDA data on record, last reported at $112.0 million in Q4 2025.

  • For Q4 2025, EBITDA rose 47.81% year-over-year to $112.0 million; the TTM value through Dec 2025 reached $394.1 million, up 58.06%, while the annual FY2025 figure was $394.1 million, 58.06% up from the prior year.
  • EBITDA reached $112.0 million in Q4 2025 per AMRX's latest filing, up from $70.3 million in the prior quarter.
  • Across five years, EBITDA topped out at $112.0 million in Q4 2025 and bottomed at -$198.6 million in Q2 2022.
  • Average EBITDA over 5 years is $45.3 million, with a median of $56.5 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 1071.05% in 2021, then tumbled 395.92% in 2022.
  • A 5-year view of EBITDA shows it stood at $11.2 million in 2021, then surged by 222.43% to $36.0 million in 2022, then tumbled by 60.61% to $14.2 million in 2023, then skyrocketed by 434.02% to $75.8 million in 2024, then skyrocketed by 47.81% to $112.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBITDA were $112.0 million in Q4 2025, $70.3 million in Q3 2025, and $111.4 million in Q2 2025.